A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies

Bruce D. Cheson, Sarit Assouline, Talha Munir, Petra Langerbeins, Constantine Tam, Gareth P. Gregory, Franck Morschhauser, Wojciech Jurczak, Michael Y. Choi, Geoffrey Shouse, Monica Tani, Gina Paris, William Sun, Siminder Kaur Atwal, Wan Jen Hong, Clementine Sarkozy

Research output: Contribution to conferencePosterpeer-review

Original languageEnglish
Number of pages1
Publication statusPublished - 2023
EventInternational Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2023) - Boston, United States of America
Duration: 6 Oct 20239 Oct 2023


ConferenceInternational Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2023)
Country/TerritoryUnited States of America

Cite this